Patent intelligence · US
US 12246064
Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
Patent details — US 12246064
- Jurisdiction
- US
- Status
- granted
- Grant date
- Mar 11, 2025
- Expiration
- Mar 6, 2045
- Applicant
- Takeda Pharmaceutical Company Limited
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545
Quick answer
US 12246064 (Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2300/00, A61K31/519
More from Takeda Pharmaceutical Company Limited
Related pharmaceutical patents in our USPTO index.
-
US 12428403
N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as SSTR4 agonists
granted -
US 12421188
Heterocyclic compound and use thereof
granted -
US 12419890
Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors
granted -
US 12415866
Monoclonal antibody inhibitor of Factor XIIa
granted -
US 12415782
Heterocyclic compound and use thereof
granted -
US 12409210
CNS delivery of therapeutic agents
granted -
US 12404237
Method of treating excessive sleepiness and/or cataplexy using n-{2-(([1,1′-biphenyl]-3-yl)methyl)pyrrolidin-3-yl}sulfonamide derivatives
granted -
US 12403154
Administration of sting agonist and checkpoint inhibitors
granted
Related coverage
Rise of Biosimilars in US: FDA Approval Trends & Market Impact
The article delves into the growing presence of biosimilars in the US market, focusing on FDA approval trends and their implications for drug pricing and patient access.
FDA Approves First Interchangeable Humira Biosimilar: Key Details
The FDA has approved the first interchangeable biosimilar to Humira, a significant milestone for patients with autoimmune conditions seeking affordable treatment alternatives.
Frequently asked questions
What is US patent 12246064?
US 12246064 (Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate) is held by Takeda Pharmaceutical Company Limited. Status: granted. Granted Mar 11, 2025. Expires Mar 6, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12246064?
Takeda Pharmaceutical Company Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 1,436 pharmaceutical patents for this assignee.
When does US 12246064 expire?
Our index shows an expiration date of Mar 6, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.